Mechanisms and Characteristics of Sulfonylureas and Glinides

American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care, 2014, 37(Suppl. 1), S14-S80.
[http://dx.doi.org/10.2337/dc14-S014] [PMID: 24357209]

Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 2006, 3(11)e442
[http://dx.doi.org/10.1371/journal.pmed.0030442] [PMID: 17132052]

Forouzanfar, M.H.; Alexander, L.; Anderson, H.R.; Bachman, V.F.; Biryukov, S.; Brauer, M.; Burnett, R.; Casey, D.; Coates, M.M.; Cohen, A.; Delwiche, K.; Estep, K.; Frostad, J.J.; Astha, K.C.; Kyu, H.H.; Moradi-Lakeh, M.; Ng, M.; Slepak, E.L.; Thomas, B.A.; Wagner, J.; Aasvang, G.M.; Abbafati, C.; Abbasoglu Ozgoren, A.; Abd-Allah, F.; Abera, S.F.; Aboyans, V.; Abraham, B.; Abraham, J.P.; Abubakar, I.; Abu-Rmeileh, N.M.; Aburto, T.C.; Achoki, T.; Adelekan, A.; Adofo, K.; Adou, A.K.; Adsuar, J.C.; Afshin, A.; Agardh, E.E.; Al Khabouri, M.J.; Al Lami, F.H.; Alam, S.S.; Alasfoor, D.; Albittar, M.I.; Alegretti, M.A.; Aleman, A.V.; Alemu, Z.A.; Alfonso-Cristancho, R.; Alhabib, S.; Ali, R.; Ali, M.K.; Alla, F.; Allebeck, P.; Allen, P.J.; Alsharif, U.; Alvarez, E.; Alvis-Guzman, N.; Amankwaa, A.A.; Amare, A.T.; Ameh, E.A.; Ameli, O.; Amini, H.; Ammar, W.; Anderson, B.O.; Antonio, C.A.; Anwari, P.; Argeseanu Cunningham, S.; Arnlöv, J.; Arsenijevic, V.S.; Artaman, A.; Asghar, R.J.; Assadi, R.; Atkins, L.S.; Atkinson, C.; Avila, M.A.; Awuah, B.; Badawi, A.; Bahit, M.C.; Bakfalouni, T.; Balakrishnan, K.; Balalla, S.; Balu, R.K.; Banerjee, A.; Barber, R.M.; Barker-Collo, S.L.; Barquera, S.; Barregard, L.; Barrero, L.H.; Barrientos-Gutierrez, T.; Basto-Abreu, A.C.; Basu, A.; Basu, S.; Basulaiman, M.O.; Batis Ruvalcaba, C.; Beardsley, J.; Bedi, N.; Bekele, T.; Bell, M.L.; Benjet, C.; Bennett, D.A.; Benzian, H.; Bernabé, E.; Beyene, T.J.; Bhala, N.; Bhalla, A.; Bhutta, Z.A.; Bikbov, B.; Bin Abdulhak, A.A.; Blore, J.D.; Blyth, F.M.; Bohensky, M.A.; Bora Başara, B.; Borges, G.; Bornstein, N.M.; Bose, D.; Boufous, S.; Bourne, R.R.; Brainin, M.; Brazinova, A.; Breitborde, N.J.; Brenner, H.; Briggs, A.D.; Broday, D.M.; Brooks, P.M.; Bruce, N.G.; Brugha, T.S.; Brunekreef, B.; Buchbinder, R.; Bui, L.N.; Bukhman, G.; Bulloch, A.G.; Burch, M.; Burney, P.G.; Campos-Nonato, I.R.; Campuzano, J.C.; Cantoral, A.J.; Caravanos, J.; Cárdenas, R.; Cardis, E.; Carpenter, D.O.; Caso, V.; Castañeda-Orjuela, C.A.; Castro, R.E.; Catalá-López, F.; Cavalleri, F.; Çavlin, A.; Chadha, V.K.; Chang, J.C.; Charlson, F.J.; Chen, H.; Chen, W.; Chen, Z.; Chiang, P.P.; Chimed-Ochir, O.; Chowdhury, R.; Christophi, C.A.; Chuang, T.W.; Chugh, S.S.; Cirillo, M.; Claßen, T.K.; Colistro, V.; Colomar, M.; Colquhoun, S.M.; Contreras, A.G.; Cooper, C.; Cooperrider, K.; Cooper, L.T.; Coresh, J.; Courville, K.J.; Criqui, M.H.; Cuevas-Nasu, L.; Damsere-Derry, J.; Danawi, H.; Dandona, L.; Dandona, R.; Dargan, P.I.; Davis, A.; Davitoiu, D.V.; Dayama, A.; de Castro, E.F.; De la Cruz-Góngora, V.; De Leo, D.; de Lima, G.; Degenhardt, L.; del Pozo-Cruz, B.; Dellavalle, R.P.; Deribe, K.; Derrett, S.; Des Jarlais, D.C.; Dessalegn, M.; deVeber, G.A.; Devries, K.M.; Dharmaratne, S.D.; Dherani, M.K.; Dicker, D.; Ding, E.L.; Dokova, K.; Dorsey, E.R.; Driscoll, T.R.; Duan, L.; Durrani, A.M.; Ebel, B.E.; Ellenbogen, R.G.; Elshrek, Y.M.; Endres, M.; Ermakov, S.P.; Erskine, H.E.; Eshrati, B.; Esteghamati, A.; Fahimi, S.; Faraon, E.J.; Farzadfar, F.; Fay, D.F.; Feigin, V.L.; Feigl, A.B.; Fereshtehnejad, S.M.; Ferrari, A.J.; Ferri, C.P.; Flaxman, A.D.; Fleming, T.D.; Foigt, N.; Foreman, K.J.; Paleo, U.F.; Franklin, R.C.; Gabbe, B.; Gaffikin, L.; Gakidou, E.; Gamkrelidze, A.; Gankpé, F.G.; Gansevoort, R.T.; García-Guerra, F.A.; Gasana, E.; Geleijnse, J.M.; Gessner, B.D.; Gething, P.; Gibney, K.B.; Gillum, R.F.; Ginawi, I.A.; Giroud, M.; Giussani, G.; Goenka, S.; Goginashvili, K.; Gomez Dantes, H.; Gona, P.; Gonzalez de Cosio, T.; González-Castell, D.; Gotay, C.C.; Goto, A.; Gouda, H.N.; Guerrant, R.L.; Gugnani, H.C.; Guillemin, F.; Gunnell, D.; Gupta, R.; Gupta, R.; Gutiérrez, R.A.; Hafezi-Nejad, N.; Hagan, H.; Hagstromer, M.; Halasa, Y.A.; Hamadeh, R.R.; Hammami, M.; Hankey, G.J.; Hao, Y.; Harb, H.L.; Haregu, T.N.; Haro, J.M.; Havmoeller, R.; Hay, S.I.; Hedayati, M.T.; Heredia-Pi, I.B.; Hernandez, L.; Heuton, K.R.; Heydarpour, P.; Hijar, M.; Hoek, H.W.; Hoffman, H.J.; Hornberger, J.C.; Hosgood, H.D.; Hoy, D.G.; Hsairi, M.; Hu, G.; Hu, H.; Huang, C.; Huang, J.J.; Hubbell, B.J.; Huiart, L.; Husseini, A.; Iannarone, M.L.; Iburg, K.M.; Idrisov, B.T.; Ikeda, N.; Innos, K.; Inoue, M.; Islami, F.; Ismayilova, S.; Jacobsen, K.H.; Jansen, H.A.; Jarvis, D.L.; Jassal, S.K.; Jauregui, A.; Jayaraman, S.; Jeemon, P.; Jensen, P.N.; Jha, V.; Jiang, F.; Jiang, G.; Jiang, Y.; Jonas, J.B.; Juel, K.; Kan, H.; Kany Roseline, S.S.; Karam, N.E.; Karch, A.; Karema, C.K.; Karthikeyan, G.; Kaul, A.; Kawakami, N.; Kazi, D.S.; Kemp, A.H.; Kengne, A.P.; Keren, A.; Khader, Y.S.; Khalifa, S.E.; Khan, E.A.; Khang, Y.H.; Khatibzadeh, S.; Khonelidze, I.; Kieling, C.; Kim, D.; Kim, S.; Kim, Y.; Kimokoti, R.W.; Kinfu, Y.; Kinge, J.M.; Kissela, B.M.; Kivipelto, M.; Knibbs, L.D.; Knudsen, A.K.; Kokubo, Y.; Kose, M.R.; Kosen, S.; Kraemer, A.; Kravchenko, M.; Krishnaswami, S.; Kromhout, H.; Ku, T.; Kuate , Defo B.; Kucuk Bicer, B.; Kuipers, E.J.; Kulkarni, C.; Kulkarni, V.S.; Kumar, G.A.; Kwan, G.F.; Lai, T.; Lakshmana Balaji, A.; Lalloo, R.; Lallukka, T.; Lam, H.; Lan, Q.; Lansingh, V.C.; Larson, H.J.; Larsson, A.; Laryea, D.O.; Lavados, P.M.; Lawrynowicz, A.E.; Leasher, J.L.; Lee, J.T.; Leigh, J.; Leung, R.; Levi, M.; Li, Y.; Li, Y.; Liang, J.; Liang, X.; Lim, S.S.; Lindsay, M.P.; Lipshultz, S.E.; Liu, S.; Liu, Y.; Lloyd, B.K.; Logroscino, G.; London, S.J.; Lopez, N.; Lortet-Tieulent, J.; Lotufo, P.A.; Lozano, R.; Lunevicius, R.; Ma, J.; Ma, S.; Machado, V.M.; MacIntyre, M.F.; Magis-Rodriguez, C.; Mahdi, A.A.; Majdan, M.; Malekzadeh, R.; Mangalam, S.; Mapoma, C.C.; Marape, M.; Marcenes, W.; Margolis, D.J.; Margono, C.; Marks, G.B.; Martin, R.V.; Marzan, M.B.; Mashal, M.T.; Masiye, F.; Mason-Jones, A.J.; Matsushita, K.; Matzopoulos, R.; Mayosi, B.M.; Mazorodze, T.T.; McKay, A.C.; McKee, M.; McLain, A.; Meaney, P.A.; Medina, C.; Mehndiratta, M.M.; Mejia-Rodriguez, F.; Mekonnen, W.; Melaku, Y.A.; Meltzer, M.; Memish, Z.A.; Mendoza, W.; Mensah, G.A.; Meretoja, A.; Mhimbira, F.A.; Micha, R.; Miller, T.R.; Mills, E.J.; Misganaw, A.; Mishra, S.; Mohamed Ibrahim, N.; Mohammad, K.A.; Mokdad, A.H.; Mola, G.L.; Monasta, L.; Montañez Hernandez, J.C.; Montico, M.; Moore, A.R.; Morawska, L.; Mori, R.; Moschandreas, J.; Moturi, W.N.; Mozaffarian, D.; Mueller, U.O.; Mukaigawara, M.; Mullany, E.C.; Murthy, K.S.; Naghavi, M.; Nahas, Z.; Naheed, A.; Naidoo, K.S.; Naldi, L.; Nand, D.; Nangia, V.; Narayan, K.M.; Nash, D.; Neal, B.; Nejjari, C.; Neupane, S.P.; Newton, C.R.; Ngalesoni, F.N.; Ngirabega, Jde.D.; Nguyen, G.; Nguyen, N.T.; Nieuwenhuijsen, M.J.; Nisar, M.I.; Nogueira, J.R.; Nolla, J.M.; Nolte, S.; Norheim, O.F.; Norman, R.E.; Norrving, B.; Nyakarahuka, L.; Oh, I.H.; Ohkubo, T.; Olusanya, B.O.; Omer, S.B.; Opio, J.N.; Orozco, R.; Pagcatipunan, R.S., Jr; Pain, A.W.; Pandian, J.D.; Panelo, C.I.; Papachristou, C.; Park, E.K.; Parry, C.D.; Paternina Caicedo, A.J.; Patten, S.B.; Paul, V.K.; Pavlin, B.I.; Pearce, N.; Pedraza, L.S.; Pedroza, A.; Pejin Stokic, L.; Pekericli, A.; Pereira, D.M.; Perez-Padilla, R.; Perez-Ruiz, F.; Perico, N.; Perry, S.A.; Pervaiz, A.; Pesudovs, K.; Peterson, C.B.; Petzold, M.; Phillips, M.R.; Phua, H.P.; Plass, D.; Poenaru, D.; Polanczyk, G.V.; Polinder, S.; Pond, C.D.; Pope, C.A.; Pope, D.; Popova, S.; Pourmalek, F.; Powles, J.; Prabhakaran, D.; Prasad, N.M.; Qato, D.M.; Quezada, A.D.; Quistberg, D.A.; Racapé, L.; Rafay, A.; Rahimi, K.; Rahimi-Movaghar, V.; Rahman, S.U.; Raju, M.; Rakovac, I.; Rana, S.M.; Rao, M.; Razavi, H.; Reddy, K.S.; Refaat, A.H.; Rehm, J.; Remuzzi, G.; Ribeiro, A.L.; Riccio, P.M.; Richardson, L.; Riederer, A.; Robinson, M.; Roca, A.; Rodriguez, A.; Rojas-Rueda, D.; Romieu, I.; Ronfani, L.; Room, R.; Roy, N.; Ruhago, G.M.; Rushton, L.; Sabin, N.; Sacco, R.L.; Saha, S.; Sahathevan, R.; Sahraian, M.A.; Salomon, J.A.; Salvo, D.; Sampson, U.K.; Sanabria, J.R.; Sanchez, L.M.; Sánchez-Pimienta, T.G.; Sanchez-Riera, L.; Sandar, L.; Santos, I.S.; Sapkota, A.; Satpathy, M.; Saunders, J.E.; Sawhney, M.; Saylan, M.I.; Scarborough, P.; Schmidt, J.C.; Schneider, I.J.; Schöttker, B.; Schwebel, D.C.; Scott, J.G.; Seedat, S.; Sepanlou, S.G.; Serdar, B.; Servan-Mori, E.E.; Shaddick, G.; Shahraz, S.; Levy, T.S.; Shangguan, S.; She, J.; Sheikhbahaei, S.; Shibuya, K.; Shin, H.H.; Shinohara, Y.; Shiri, R.; Shishani, K.; Shiue, I.; Sigfusdottir, I.D.; Silberberg, D.H.; Simard, E.P.; Sindi, S.; Singh, A.; Singh, G.M.; Singh, J.A.; Skirbekk, V.; Sliwa, K.; Soljak, M.; Soneji, S.; Søreide, K.; Soshnikov, S.; Sposato, L.A.; Sreeramareddy, C.T.; Stapelberg, N.J.; Stathopoulou, V.; Steckling, N.; Stein, D.J.; Stein, M.B.; Stephens, N.; Stöckl, H.; Straif, K.; Stroumpoulis, K.; Sturua, L.; Sunguya, B.F.; Swaminathan, S.; Swaroop, M.; Sykes, B.L.; Tabb, K.M.; Takahashi, K.; Talongwa, R.T.; Tandon, N.; Tanne, D.; Tanner, M.; Tavakkoli, M.; Te Ao, B.J.; Teixeira, C.M.; Téllez Rojo, M.M.; Terkawi, A.S.; Texcalac-Sangrador, J.L.; Thackway, S.V.; Thomson, B.; Thorne-Lyman, A.L.; Thrift, A.G.; Thurston, G.D.; Tillmann, T.; Tobollik, M.; Tonelli, M.; Topouzis, F.; Towbin, J.A.; Toyoshima, H.; Traebert, J.; Tran, B.X.; Trasande, L.; Trillini, M.; Trujillo, U.; Dimbuene, Z.T.; Tsilimbaris, M.; Tuzcu, E.M.; Uchendu, U.S.; Ukwaja, K.N.; Uzun, S.B.; van de Vijver, S.; Van Dingenen, R.; van Gool, C.H.; van Os, J.; Varakin, Y.Y.; Vasankari, T.J.; Vasconcelos, A.M.; Vavilala, M.S.; Veerman, L.J.; Velasquez-Melendez, G.; Venketasubramanian, N.; Vijayakumar, L.; Villalpando, S.; Violante, F.S.; Vlassov, V.V.; Vollset, S.E.; Wagner, G.R.; Waller, S.G.; Wallin, M.T.; Wan, X.; Wang, H.; Wang, J.; Wang, L.; Wang, W.; Wang, Y.; Warouw, T.S.; Watts, C.H.; Weichenthal, S.; Weiderpass, E.; Weintraub, R.G.; Werdecker, A.; Wessells, K.R.; Westerman, R.; Whiteford, H.A.; Wilkinson, J.D.; Williams, H.C.; Williams, T.N.; Woldeyohannes, S.M.; Wolfe, C.D.; Wong, J.Q.; Woolf, A.D.; Wright, J.L.; Wurtz, B.; Xu, G.; Yan, L.L.; Yang, G.; Yano, Y.; Ye, P.; Yenesew, M.; Yentür, G.K.; Yip, P.; Yonemoto, N.; Yoon, S.J.; Younis, M.Z.; Younoussi, Z.; Yu, C.; Zaki, M.E.; Zhao, Y.; Zheng, Y.; Zhou, M.; Zhu, J.; Zhu, S.; Zou, X.; Zunt, J.R.; Lopez, A.D.; Vos, T.; Murray, C.J. GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 386(10010), 2287-2323.
[http://dx.doi.org/10.1016/S0140-6736(15)00128-2] [PMID: 26364544]

Danaei, G.; Finucane, M.M.; Lu, Y.; Singh, G.M.; Cowan, M.J.; Paciorek, C.J.; Lin, J.K.; Farzadfar, F.; Khang, Y.H.; Stevens, G.A.; Rao, M.; Ali, M.K.; Riley, L.M.; Robinson, C.A.; Ezzati, M. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group.(Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet, 2011, 378(9785), 31-40.
[http://dx.doi.org/10.1016/S0140-6736(11)60679-X] [PMID: 21705069]

Ogurtsova, K.; da Rocha Fernandes, J.D.; Huang, Y.; Linnenkamp, U.; Guariguata, L.; Cho, N.H.; Cavan, D.; Shaw, J.E.; Makaroff, L.E. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res. Clin. Pract., 2017, 128, 40-50.
[http://dx.doi.org/10.1016/j.diabres.2017.03.024] [PMID: 28437734]

World Health Organization The top 10 causes of death fact sheet., 2017.Available from . https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

Cnop, M.; Welsh, N.; Jonas, J.C.; Jörns, A.; Lenzen, S.; Eizirik, D.L. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes, 2005, 54(Suppl. 2), S97-S107.
[http://dx.doi.org/10.2337/diabetes.54.suppl_2.S97] [PMID: 16306347 ]

Halim, M.; Halim, A. The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). Diabetes Metab. Syndr., 2019, 13(2), 1165-1172.
[http://dx.doi.org/10.1016/j.dsx.2019.01.040] [PMID: 31336460 ]

Salgin, B.; Ong, K.K.; Thankamony, A.; Emmett, P.; Wareham, N.J.; Dunger, D.B. Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes. J. Clin. Endocrinol. Metab., 2012, 97(9), 3302-3309.
[http://dx.doi.org/10.1210/jc.2012-1428] [PMID: 22740706]

Rendell, M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs, 2004, 64(12), 1339-1358.
[http://dx.doi.org/10.2165/00003495-200464120-00006] [PMID: 15200348]

Houssay, B.A.; Penhos, J.C.; Teodosio, N.; Bowkett, J.; Apelbaum, J. Action of the hypoglycemic sulfonyl compounds in hypophysectomized, adrenalectomized, and depancreatized animals. Ann. N. Y. Acad. Sci., 1957, 71(1), 12-24.
[http://dx.doi.org/10.1111/j.1749-6632.1957.tb54570.x] [PMID: 13459195]

Loubatières, A. The mechanism of action of the hypoglycemic sulfonamides: a concept based on investigations in animals and in human beings. Ann. N. Y. Acad. Sci., 1957, 71(1), 192-206.
[http://dx.doi.org/10.1111/j.1749-6632.1957.tb54591.x] [PMID: 13459216]

Seino, S.; Miki, T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog. Biophys. Mol. Biol., 2003, 81(2), 133-176.
[http://dx.doi.org/10.1016/S0079-6107(02)00053-6] [PMID: 12565699]

Tinker, A.; Aziz, Q.; Li, Y.; Specterman, M. ATP-sensitive potassium channels and their physiological and pathophysiological roles. Compr. Physiol., 2018, 8(4), 1463-1511.
[http://dx.doi.org/10.1002/cphy.c170048] [PMID: 30215858]

Gribble, F.M.; Reimann, F. Sulphonylurea action revisited: the post-cloning era. Diabetologia, 2003, 46(7), 875-891.
[http://dx.doi.org/10.1007/s00125-003-1143-3] [PMID: 12819907]

Przibilla, J.; Dembla, S.; Rizun, O.; Lis, A.; Jung, M.; Oberwinkler, J.; Beck, A.; Philipp, S.E. Ca²⁺-dependent regulation and binding of calmodulin to multiple sites of Transient Receptor Potential Melastatin 3 (TRPM3) ion channels. Cell Calcium, 2018, 73, 40-52.
[http://dx.doi.org/10.1016/j.ceca.2018.03.005] [PMID: 29880196]

Sulis, P.M.; Dambrós, B.F.; Mascarello, A.; Dos Santos, A.R.S.; Yunes, R.A.; Nunes, R.J.; Frederico, M.J.S.; Barreto Silva, F.R.M. Sulfonyl(thio)urea derivative induction of insulin secretion is mediated by potassium, calcium, and sodium channel signal transduction. J. Cell. Physiol., 2019, 234(7), 10138-10147.
[http://dx.doi.org/10.1002/jcp.27680] [PMID: 30417369]

Berggren, P.O.; Larsson, O. Ca2+ and pancreatic B-cell function. Biochem. Soc. Trans., 1994, 22(1), 12-18.
[http://dx.doi.org/10.1042/bst0220012] [PMID: 8206203]

Proks, P.; Clark, R. The role of two pore channels (TPCs) in pancreatic beta cell stimulus-secretion coupling; University of Oxford: Oxford, 2014.

Heister, P.M. The role of two pore channels (TPCs) in pancreatic beta cell stimulus-secretion coupling; University of Oxford, 2012.

Ashcroft, S.J.H.; Niki, I.; Kenna, S.; Weng, L.; Skeer, J.; Coles, B.; Ashcroft, F.M. The β-cell sulfonylurea receptor. Adv. Exp. Med. Biol., 1993, 334, 47-61.
[http://dx.doi.org/10.1007/978-1-4615-2910-1_4] [PMID: 8249695]

Hellman, B.; Gylfe, E.; Grapengiesser, E.; Lund, P-E.; Berts, A. Biochim. Biophys. Acta Rev. Biomembr., 1992, 1113, 295-305.
[http://dx.doi.org/10.1016/0304-4157(92)90003-S]

Schofield, C.J.; Sutherland, C. Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes. Diabet. Med., 2012, 29(8), 972-979.
[http://dx.doi.org/10.1111/j.1464-5491.2012.03655.x] [PMID: 22443306]

Alexander, S.P.H.; Benson, H.E.; Faccenda, E.; Pawson, A.J.; Sharman, J.L.; Catterall, W.A.; Spedding, M.; Peters, J.A.; Harmar, A.J. CGTP collaborators.The concise guide to pharmacology 2013/14: ion channels. Br. J. Pharmacol., 2013, 170(8), 1607-1651.
[http://dx.doi.org/10.1111/bph.12447] [PMID: 24528239]

Alexander, S.P.H.; Benson, H.E.; Faccenda, E.; Pawson, A.J.; Sharman, J.L.; Spedding, M.; Peters, J.A.; Harmar, A.J. CGTP collaborators.The concise guide to pharmacology 2013/14: enzymes. Br. J. Pharmacol., 2013, 170(8), 1797-1867.
[http://dx.doi.org/10.1111/bph.12451] [PMID: 24528243]

Alexander, S.P.H.; Benson, H.E.; Faccenda, E.; Pawson, A.J.; Sharman, J.L.; Spedding, M.; Peters, J.A.; Harmar, A.J. CGTP collaborators. the concise guide to pharmacology 2013/14: transporters. Br. J. Pharmacol., 2013, 170(8), 1706-1796.
[http://dx.doi.org/10.1111/bph.12450] [PMID: 24528242]

Alexander, S.P.H.; Benson, H.E.; Faccenda, E.; Pawson, A.J.; Sharman, J.L.; Spedding, M.; Peters, J.A.; Harmar, A.J. CGTP collaborators. the concise guide to pharmacology 2013/14: nuclear hormone receptors. Br. J. Pharmacol., 2013, 170(8), 1652-1675.
[http://dx.doi.org/10.1111/bph.12448] [PMID: 24528240]

Antcliff, J.F.; Haider, S.; Proks, P.; Sansom, M.S.; Ashcroft, F.M. Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. EMBO J., 2005, 24(2), 229-239.
[http://dx.doi.org/10.1038/sj.emboj.7600487] [PMID: 15650751]

Ashcroft, S.J.H.; Ashcroft, F.M. The sulfonylurea receptor. Biochim. Biophys. Acta, 1992, 1175, 45-59.

Ashcroft, S.J.H.; Ashcroft, F.M. Hormones and Cell Regulation Nunez, J. and Dumont, J.E., Eds.; Colloque INSERM/J. Libbey Eurotext: Paris, . 1989, 198, pp. 99-103.

Ashcroft, S.J.; Niki, I.; Kenna, S.; Weng, L.; Skeer, J.; Coles, B.; Ashcroft, F.M. The beta-cell sulfonylurea receptor. Adv. Exp. Med. Biol., 1993, 334, 47-61.
[http://dx.doi.org/10.1007/978-1-4615-2910-1_4] [PMID: 8249695]

Seino, S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol., 1999, 61, 337-362.
[http://dx.doi.org/10.1146/annurev.physiol.61.1.337] [PMID: 10099692]

Inagaki, N.; Gonoi, T.; Clement, J.P., IV; Namba, N.; Inazawa, J.; Gonzalez, G.; Aguilar-Bryan, L.; Seino, S.; Bryan, J. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science, 1995, 270(5239), 1166-1170.
[http://dx.doi.org/10.1126/science.270.5239.1166] [PMID: 7502040]

Sakura, H.; Ammala, C.; Smith, P.A.; Gribble, F.M.; Ashcroft, F.M. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle. FEBS Lett., 1995, 377(3), 338-344.
[http://dx.doi.org/10.1016/0014-5793(95)01369-5] [PMID: 8549751]

Seino, S.; Sugawara, K.; Yokoi, N.; Takahashi, H. β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy. Diabetes Obes. Metab., 2017, 19(Suppl. 1), 22-29.
[http://dx.doi.org/10.1111/dom.12995] [PMID: 28880474]

Gribble, F.M.; Tucker, S.J.; Seino, S.; Ashcroft, F.M. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes, 1998, 47(9), 1412-1418.
[http://dx.doi.org/10.2337/diabetes.47.9.1412] [PMID: 9726229]

Quast, U.; Stephan, D.; Bieger, S.; Russ, U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes, 2004, 53(Suppl. 3), S156-S164.
[http://dx.doi.org/10.2337/diabetes.53.suppl_3.S156] [PMID: 15561904]

Bienengraeber, M.; Alekseev, A.E.; Abraham, M.R.; Carrasco, A.J.; Moreau, C.; Vivaudou, M.; Dzeja, P.P.; Terzic, A. ATPase activity of the sulfonylurea receptor: a catalytic function for the KATP channel complex. FASEB J., 2000, 14(13), 1943-1952.
[http://dx.doi.org/10.1096/fj.00-0027com] [PMID: 11023978]

Inagaki, N.; Tsuura, Y.; Namba, N.; Masuda, K.; Gonoi, T.; Horie, M.; Seino, Y.; Mizuta, M.; Seino, S. Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle, and heart. J. Biol. Chem., 1995, 270(11), 5691-5694.
[http://dx.doi.org/10.1074/jbc.270.11.5691] [PMID: 7890693]

Seino, S.; Takahashi, H.; Takahashi, T.; Shibasaki, T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes. Metab., 2012, 14(Suppl. 1), 9-13.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01507.x] [PMID: 22118705]

Seino, S.; Zhang, C.L.; Shibasaki, T. Sulfonylurea action re-revisited. J. Diabetes Investig., 2010, 1(1-2), 37-39.
[http://dx.doi.org/10.1111/j.2040-1124.2010.00014.x] [PMID: 24843406]

Ashcroft, F.M.; Rorsman, P. K(ATP) channels and islet hormone secretion: new insights and controversies. Nat. Rev. Endocrinol., 2013, 9(11), 660-669.
[http://dx.doi.org/10.1038/nrendo.2013.166] [PMID: 24042324]

Miki, T.; Nagashima, K.; Tashiro, F.; Kotake, K.; Yoshitomi, H.; Tamamoto, A.; Gonoi, T.; Iwanaga, T.; Miyazaki, J.; Seino, S. Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc. Natl. Acad. Sci. USA, 1998, 95(18), 10402-10406.
[http://dx.doi.org/10.1073/pnas.95.18.10402] [PMID: 9724715]

Seghers, V.; Nakazaki, M.; DeMayo, F.; Aguilar-Bryan, L.; Bryan, J. Sur1 knockout mice. A model for K(ATP) channel-independent regulation of insulin secretion. J. Biol. Chem., 2000, 275(13), 9270-9277.
[http://dx.doi.org/10.1074/jbc.275.13.9270] [PMID: 10734066]

Shiota, C.; Larsson, O.; Shelton, K.D.; Shiota, M.; Efanov, A.M.; Hoy, M.; Lindner, J.; Kooptiwut, S.; Juntti-Berggren, L.; Gromada, J.; Berggren, P.O.; Magnuson, M.A. Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J. Biol. Chem., 2002, 277(40), 37176-37183.
[http://dx.doi.org/10.1074/jbc.M206757200] [PMID: 12149271]

Flanagan, S.E.; Clauin, S.; Bellanné-Chantelot, C.; de Lonlay, P.; Harries, L.W.; Gloyn, A.L.; Ellard, S. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum. Mutat., 2009, 30(2), 170-180.
[http://dx.doi.org/10.1002/humu.20838] [PMID: 18767144]

Babenko, A.P.; Gonzalez, G.; Aguilar-Bryan, L.; Bryan, J. Reconstituted human cardiac KATP channels: functional identity with the native channels from the sarcolemma of human ventricular cells. Circ. Res., 1998, 83(11), 1132-1143.
[http://dx.doi.org/10.1161/01.RES.83.11.1132] [PMID: 9831708]

Lorenz, E.; Terzic, A. Physical association between recombinant cardiac ATP-sensitive K+ channel subunits Kir6.2 and SUR2A. J. Mol. Cell. Cardiol., 1999, 31(2), 425-434.
[http://dx.doi.org/10.1006/jmcc.1998.0876] [PMID: 10093054]

Inagaki, N.; Gonoi, T.; Clement, J.P.; Wang, C.Z. Aguilar- Bryan, L., Bryan, J., and Seino, S. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K1 channels. Neuron, 1996, 16, 1011-1017.
[http://dx.doi.org/10.1016/S0896-6273(00)80124-5] [PMID: 8630239]

Russ, U.; Hambrock, A.; Artunc, F. Loffler- Walz, C., Horio, Y., Kurachi, Y., and Quast, U. Coexpression with the inward rectifier K(1) channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide. Mol. Pharmacol., 1999, 56, 955-961.
[http://dx.doi.org/10.1124/mol.56.5.955] [PMID: 10531400]

Satoh, E.; Yamada, M.; Kondo, C.; Repunte, V.P.; Horio, Y.; Iijima, T.; Kurachi, Y. Intracellular nucleotide-mediated gating of SUR/Kir6.0 complex potassium channels expressed in a mammalian cell line and its modification by pinacidil. J. Physiol., 1998, 511(Pt 3), 663-674.
[http://dx.doi.org/10.1111/j.1469-7793.1998.663bg.x] [PMID: 9714850]

Thorneloe, K.S.; Maruyama, Y.; Malcolm, A.T.; Light, P.E.; Walsh, M.P.; Cole, W.C. Protein kinase C modulation of recombinant ATP-sensitive K(+) channels composed of Kir6.1 and/or Kir6.2 expressed with SUR2B. J. Physiol., 2002, 541(Pt 1), 65-80.
[http://dx.doi.org/10.1113/jphysiol.2002.018101] [PMID: 12015420]

Kramer, W. The molecular interaction of sulfonylureas withβ-cell ATP-sensitive K+-channels. Diabetes Res. Clin. Pract.28, 1995, S67-S80.

Müller, G.; Satoh, Y.; Geisen, K. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas. Diabetes Res. Clin. Pract., 1995, 28(Suppl.), S115-S137.
[http://dx.doi.org/10.1016/0168-8227(95)01089-V] [PMID: 8529504]

Campbell, K.P.; Leung, A.T.; Sharp, A.H. The biochemistry and molecular biology of the dihydropyridine-sensitive calcium channel. Trends Neurosci., 1988, 11(10), 425-430.
[http://dx.doi.org/10.1016/0166-2236(88)90193-2] [PMID: 2469159]

Seino, S.; Chen, L.; Seino, M. Blonde1 0, Takeda J, Johnson JH, Bell GI Cloning of the a1 subunit of voltage dependent calcium channels expressed in pancreatic p-cells. Proc. Natl. Acad. Sci. USA, 1992, 89, 584-588.
[http://dx.doi.org/10.1073/pnas.89.2.584] [PMID: 1309948]

Perez-Reyes, E.; Wei, X.; Catellano, A.; Birnbaumer, L. Molecular diversity of L-type Ca2+ channels. J. Biol. Chem., 1990, 265, 20430-20436.
[PMID: 2173707]

Petersen, O.H.; Findlay, I. Electrophysiology of the pancreas. Physiol. Rev., 1987, 67(3), 1054-1116.
[http://dx.doi.org/10.1152/physrev.1987.67.3.1054] [PMID: 2440063]

Ashcroft, F.M. Adenosine 5′-triphosphate-sensitive potassium channels. Annu. Rev. Neurosci., 1988, 11, 97-118.
[http://dx.doi.org/10.1146/annurev.ne.11.030188.000525] [PMID: 2452599]

Satin, L.S.; Hopkins, W.F.; Fatherazi, S.; Cook, D.L. Expression of a rapid, low-voltage threshold K current in insulin-secreting cells is dependent on intracellular calcium buffering. J. Membr. Biol., 1989, 112(3), 213-222.
[http://dx.doi.org/10.1007/BF01870952] [PMID: 2515282]

Boyd, A.E. III Sulfonylurea receptors, ion channels, and fruit flies. Diabetes, 1988, 37(7), 847-850.
[http://dx.doi.org/10.2337/diab.37.7.847] [PMID: 2454858]

Bokvist, K.; Rorsman, P.; Smith, P.A. Effects of external tetraethylammonium ions and quinine on delayed rectifying K+ channels in mouse pancreatic β-cells. J. Physiol., 1990, 423, 311-325.
[http://dx.doi.org/10.1113/jphysiol.1990.sp018024] [PMID: 2201760]

Smith, P.A.; Bokvist, K.; Arkhammar, P.; Berggren, P.O.; Rorsman, P. Delayed rectifying and calcium-activated K+ channels and their significance for action potential repolarization in mouse pancreatic β-cells. J. Gen. Physiol., 1990, 95(6), 1041-1059.
[http://dx.doi.org/10.1085/jgp.95.6.1041] [PMID: 2197368]

Philipson, L.H.; Hice, R.E.; Schaefer, K. Sequence and functional expression in Xenopus oocytes of a human insulinoma and islet potassium channel. Proc. Natl. Acad. Sci. USA. Neurobiology, 1991, (88), 53-57.

Wollheim, C.B.; Sharp, G.W.G. Regulation of insulin release by calcium. Physiol. Rev., 1981, 61(4), 914-973.
[http://dx.doi.org/10.1152/physrev.1981.61.4.914] [PMID: 6117094]

Prentki, M.; Matschinsky, F. Ca2+, cAMP, and in coupling mechanisms of insulin secretion. Physiol. Rev., 1987, 67, 1185-1248.
[http://dx.doi.org/10.1152/physrev.1987.67.4.1185] [PMID: 2825225]

Bond, C.T.; Ammala, C.; Ashfield, R.; Blair, T.A.; Gribble, F.; Khan, R.N.; Lee, K.; Proks, P.; Rowe, I.C.; Sakura, H. Cloning and functional expression of the cDNA encoding an inwardly-rectifying potassium channel expressed in pancreatic β-cells and in the brain. FEBS Lett., 1995, 367(1), 61-66.
[http://dx.doi.org/10.1016/0014-5793(95)00497-W] [PMID: 7601286]

Aguilar-Bryan, L.; Nichols, C.G.; Wechsler, S.W.; Clement, J.P.; Boyd, A.E.; Gonzalez, G.; Herrera-Sosa, H.; Nguy, K.; Bryan, J.; Nelson, D.A. Cloning of theβ-cell highaffinity sulphonylurea receptor: a regulator of insulin secretion. Science, 1995, 268, 423-425.
[http://dx.doi.org/10.1126/science.7716547] [PMID: 7716547]

Daniel, L. The B-cell response to oral hypoglycemic agents. Diabetes Res. Clin. Pract., 1995, 28, 581-589.

Gribble, F.M.; Tucker, S.J.; Ashcroft, F.M. The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation. J. Physiol., 1997, 504(Pt 1), 35-45.
[http://dx.doi.org/10.1111/j.1469-7793.1997.00035.x] [PMID: 9350615]

Ashcroft, F.M.; Proks, P.; Smith, P.A.; Ammala, C.; Bokvist, K.; Rorsman, P. Stimulus-secretion coupling in pancreatic β cells. J. Cell. Biochem., 1994, 55(Suppl.), 54-65.
[http://dx.doi.org/10.1002/jcb.240550007] [PMID: 7929618]

Gloyn, A.L.; Weedon, M.N.; Owen, K.R.; Turner, M.J.; Knight, B.A.; Hitman, G.; Walker, M.; Levy, J.C.; Sampson, M.; Halford, S.; McCarthy, M.I.; Hattersley, A.T.; Frayling, T.M. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes, 2003, 52(2), 568-572.
[http://dx.doi.org/10.2337/diabetes.52.2.568] [PMID: 12540637]

Michael, V. Mikhailov, Ellina A. Mikhailova, Stephen J.H. Ashcroft,Investigation of the molecular assembly of L-cell KATP channels. FEBS Lett., 2000, 48259-48264.

Idevall-Hagren, O; Jakobsson, I; Xu, Y; Tengholm, A. Spatial control of Epac2 activity by cAMP and Ca2+-mediated activation of Ras in pancreatic β cells Sci Signal 6(273), 2013. ra29.1-11, S1-6

Skelin, M.; Rupnik, M. cAMP increases the sensitivity of exocytosis to Ca²+ primarily through protein kinase A in mouse pancreatic beta cells. Cell Calcium, 2011, 49(2), 89-99.
[http://dx.doi.org/10.1016/j.ceca.2010.12.005] [PMID: 21242000]

Takahashi, H.; Shibasaki, T.; Park, J.H. Po147 Interplay between incretin and sulfonylurea through Epac2A/Rap1 signaling in insulin secretion. Diabetes, 2015, 9(4), 1262.
[http://dx.doi.org/10.2337/db14-0576] [PMID: 25315008]

Zhang, C.L.; Katoh, M.; Shibasaki, T.; Minami, K.; Sunaga, Y.; Takahashi, H.; Yokoi, N.; Iwasaki, M.; Miki, T.; Seino, S. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science, 2009, 325(5940), 607-610.
[http://dx.doi.org/10.1126/science.1172256] [PMID: 19644119]

Robichaux, W.G., III; Cheng, X. Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development. Physiol. Rev., 2018, 98(2), 919-1053.
[http://dx.doi.org/10.1152/physrev.00025.2017] [PMID: 29537337]

Shibasaki, T.; Takahashi, H.; Miki, T.; Sunaga, Y.; Matsumura, K.; Yamanaka, M.; Zhang, C.; Tamamoto, A.; Satoh, T.; Miyazaki, J.; Seino, S. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc. Natl. Acad. Sci. USA, 2007, 104(49), 19333-19338.
[http://dx.doi.org/10.1073/pnas.0707054104] [PMID: 18040047]

Ozaki, N.; Shibasaki, T.; Kashima, Y.; Miki, T.; Takahashi, K.; Ueno, H.; Sunaga, Y.; Yano, H.; Matsuura, Y.; Iwanaga, T.; Takai, Y.; Seino, S. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat. Cell Biol., 2000, 2(11), 805-811.
[http://dx.doi.org/10.1038/35041046] [PMID: 11056535]

Shibasaki, T. Elucidation of the function and role of cAMP sensor Epac2A in insulin secretion. Diabetol. Int., 2012, 3(4), 187-196.
[http://dx.doi.org/10.1007/s13340-012-0094-7]

Shibasaki, T.; Takahashi, T.; Takahashi, H.; Seino, S. Cooperation between cAMP signalling and sulfonylurea in insulin secretion. Diabetes Obes. Metab., 2014, 16(Suppl. 1), 118-125.
[http://dx.doi.org/10.1111/dom.12343] [PMID: 25200305]

Naim, M.; Bhat, S.; Rankin, K.N.; Dennis, S.; Chowdhury, S.F.; Siddiqi, I.; Drabik, P.; Sulea, T.; Bayly, C.I.; Jakalian, A.; Purisima, E.O. Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space. J. Chem. Inf. Model., 2007, 47(1), 122-133.
[http://dx.doi.org/10.1021/ci600406v] [PMID: 17238257]

Takahashi, T.; Shibasaki, T.; Takahashi, H.; Sugawara, K.; Ono, A.; Inoue, N.; Furuya, T.; Seino, S. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci. Signal., 2013, 6(298), ra94.
[http://dx.doi.org/10.1126/scisignal.2004581] [PMID: 24150255]

Bos, J.L. Epac proteins: multi-purpose cAMP targets. Trends Biochem. Sci., 2006, 31(12), 680-686.
[http://dx.doi.org/10.1016/j.tibs.2006.10.002] [PMID: 17084085]

Jarrard, R.E.; Wang, Y.; Salyer, A.E.; Pratt, E.P.; Soderling, I.M.; Guerra, M.L.; Lange, A.M.; Broderick, H.J.; Hockerman, G.H. Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx. Mol. Pharmacol., 2013, 83(1), 191-205.
[http://dx.doi.org/10.1124/mol.112.081943] [PMID: 23071106]

Marshall, A.; Gingerich, R.L.; Wright, P.H. Hepatic effect of sulfonylureas. Metabolism, 1970, 19(12), 1046-1052.
[http://dx.doi.org/10.1016/0026-0495(70)90028-4] [PMID: 5492043]

Barzilai, N.; Groop, P-H.; Groop, L.; DeFronzo, R.A. A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. Acta Diabetol., 1995, 32(4), 273-278.
[http://dx.doi.org/10.1007/BF00576262] [PMID: 8750768]

Cefalu, W.; Kourides, I.; Fischette, C. Glipizide GITS vs immediate-release glipizide in the managment of patient with NIDDM. Diabetes, 1994, 43(Suppl. 1), 59A.

Simonson, D.C.; Kourides, I.; Fischette, C. Efficacy and safety of glipizide GITS in the treatment of non-insulin-dependent diabetes mellitus. Diabetes, 1994, 43(Suppl. 1), 63A.

Widen, E; Blomqvist, A-C; Erikson, J; Groop, L Effects of glibenclamide on clearance of insulin in type 2 diabetes (abstract). Acta Endocrinol,, 1991, t24(Suppl 3), 40.

Cryer Minireview, E. Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes philip. Endocrinology, 2012, 153(3), 1039-1048.
[http://dx.doi.org/10.1210/en.2011-1499] [PMID: 22166985]

ter Braak, E.W.; Appelman, A.M.; van der Tweel, I.; Erkelens, D.W.; van Haeften, T.W. The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. Diabetes Care, 2002, 25(1), 107-112.
[http://dx.doi.org/10.2337/diacare.25.1.107] [PMID: 11772910]

Bohannon, NV; Lorenzi, M; Grodsky, GM; Karam, JH Stimulatory effects of tolbutamide infusion on plasma glucagon in insulindependent diabetic subjects, J Clin Endocrinol Metab,.

Landstedt-Hallin, L.; Adamson, U.; Lins, P.E. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 1999, 84(9), 3140-3145.
[http://dx.doi.org/10.1210/jc.84.9.3140] [PMID: 10487677]

Rossetti, L.; Giaccari, A.; DeFronzo, R.A. Glucose toxicity. Diabetes Care, 1990, 13(6), 610-630.
[http://dx.doi.org/10.2337/diacare.13.6.610] [PMID: 2192847]

Mandarino, L.J.; Gerich, J.E. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes Care, 1984, 7(Suppl. 1), 89-99.
[PMID: 6376034]

Müller, G. Dynamics of plasma membrane microdomains and cross-talk to the insulin signalling cascade. FEBS Lett., 2002, 531(1), 81-87.
[http://dx.doi.org/10.1016/S0014-5793(02)03402-6] [PMID: 12401208]

Müller, G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol. Med., 2000, 6(11), 907-933.
[http://dx.doi.org/10.1007/BF03401827] [PMID: 11147570]

Arrault, A.; Rocchi, S.; Picard, F.; Maurois, P.; Pirotte, B.; Vamecq, J. A short series of antidiabetic sulfonylureas exhibit multiple ligand PPARgamma-binding patterns. Biomed. Pharmacother., 2009, 63(1), 56-62.
[http://dx.doi.org/10.1016/j.biopha.2007.12.007] [PMID: 18280694]

Peter, M. Thulé & Guillermo Umpierrez, Sulfonylureas a new look at old therapy. Curr. Diab. Rep., 2014, 14, 473.
[http://dx.doi.org/10.1007/s11892-014-0473-5]

Basit, A.; Riaz, M.; Fawwad, A. Glimepiride: evidence-based facts, trends, and observations (GIFTS)[corrected]. Vasc. Health Risk Manag., 2012, 8, 463-472.
[http://dx.doi.org/10.2147/VHRM.S33194] [PMID: 23028231]

Nyenwe, EA; Jerkins, TW; Umpierrez, GE; Kitabchi, AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.Metabolism. Up-to-date review of pharmacological agents available for the management of patients with diabetes type 2. Metabolism, 2011, 60(1), 1-23.
[http://dx.doi.org/10.1016/j.metabol.2010.09.010]

Andrew Krentz et al. Do sulfonylureas still have a role in type 2 diabetes? Prescriber, 2011, 22(10), 33-36.

Schopman, J.E.; Simon, A.C.; Hoefnagel, S.J.; Hoekstra, J.B.; Scholten, R.J.; Holleman, F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab. Res. Rev., 2014, 30(1), 11-22.
[http://dx.doi.org/10.1002/dmrr.2470] [PMID: 24030920]

Avogaro, A. Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes Obes. Metab., 2012, 14(Suppl. 1), 14-19.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01508.x] [PMID: 22118706]

Aquilante, C.L. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev. Cardiovasc. Ther., 2010, 8(3), 359-372.
[http://dx.doi.org/10.1586/erc.09.154] [PMID: 20222815]

Nakano, N.; Miyazawa, N.; Sakurai, T.; Kizaki, T.; Kimoto, K.; Takahashi, K.; Ishida, H.; Takahashi, M.; Suzuki, K.; Ohno, H. Gliclazide inhibits proliferation but stimulates differentiation of white and brown adipocytes. J. Biochem., 2007, 142(5), 639-645.
[http://dx.doi.org/10.1093/jb/mvm172] [PMID: 17965069]

Sena, C.M.; Louro, T.; Matafome, P.; Nunes, E.; Monteiro, P.; Seiça, R. Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiol. Res., 2009, 58(2), 203-209.
[PMID: 18380531]

Kim, J.S.; Kim, I.K.; Lee, S.Y.; Song, B.W.; Cha, M.J.; Song, H.; Choi, E.; Lim, S.; Ham, O.; Jang, Y.; Hwang, K.C. Anti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway. Cell Biol. Int., 2012, 36(3), 305-310.
[http://dx.doi.org/10.1042/CBI20100524] [PMID: 22050182]

Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia, 2004, 47(11), 1906-1913.
[http://dx.doi.org/10.1007/s00125-004-1547-8] [PMID: 15565373]

Lee, K.Y.; Kim, J.R.; Choi, H.C. Gliclazide, a K_ATP channel blocker, inhibits vascular smooth muscle cell proliferation through the CaMKKβ-AMPK pathway. Vascul. Pharmacol., 2018, 102, 21-28.
[http://dx.doi.org/10.1016/j.vph.2018.01.001] [PMID: 29337033]

Mary, T.; Korytkowski, M.D. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride, pharmacotherapy. Journal of Human Pharmacology and Drug Therapy, 2004, 24(5), 606-620.
[http://dx.doi.org/10.1592/phco.24.6.606.34752]

Lawrence, J.C., Jr; Hiken, J.F.; James, D.E.; Hiken, J.F.; James, D.E. Stimulation of glucose transport and glucose transporter phosphorylation by okadaic acid in rat adipocytes. J. Biol. Chem., 1990, 265(32), 19768-19776.
[PMID: 2174052]

Lawrence, J.C., Jr; Hiken, J.F.; James, D.E. Phosphorylation of the glucose transporter in rat adipocytes. Identification of the intracellular domain at the carboxyl terminus as a target for phosphorylation in intact-cells and in vitro. J. Biol. Chem., 1990, 265(4), 2324-2332.
[PMID: 2404983]

Chen, H.; Hamel, F.G.; Siford, G.; Duckworth, W.C. Alteration of rat hepatic insulin metabolism by glyburide and glipizide. J. Pharmacol. Exp. Ther., 1993, 264(3), 1293-1298.
[PMID: 8450464]

Sato, J.; Ohsawa, I.; Oshida, Y.; Sato, Y.; Sakamoto, N. Effects of glimepiride on in vivo insulin action in normal and diabetic rats. Diabetes Res. Clin. Pract., 1993, 22(1), 3-9.
[http://dx.doi.org/10.1016/0168-8227(93)90126-P] [PMID: 8137714]

Del Guerra, S.; Parentini, C.; Bracci, C.; Lupi, R.; Marselli, L.; Aragona, M.; Navalesi, R.; Marchetti, P. Insulin release form isolated, human islets after acute or prolonged exposure to glimepiride. Acta Diabetol., 2000, 37(3), 139-141.
[http://dx.doi.org/10.1007/s005920070017] [PMID: 11277315]

Gregorio, F.; Santeusanio, F.; Filipponi, P.; Cristallini, S.; Ambrosi, F. Effects of glimepiride on from isolated rat pancreas at different glucose concentrations. Acta Diabetol., 1996, 33, 25-29.
[http://dx.doi.org/10.1007/BF00571936] [PMID: 8777281]

Marchetti, P.; Dotta, F.; Ling, Z.; Lupi, R.; Del Guerra, S.; Santangelo, C.; Realacci, M.; Marselli, L.; Di Mario, U.; Navalesi, R. Function of pancreatic islets isolated from a type 1 diabetic patient. Diabetes Care, 2000, 23(5), 701-703.
[http://dx.doi.org/10.2337/diacare.23.5.701] [PMID: 10834434]

Pupilli, C.; Giannini, S.; Marchetti, P.; Lupi, R.; Antonelli, A.; Malavasi, F.; Takasawa, S.; Okamoto, H.; Ferrannini, E. Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets. Diabetes, 1999, 48(12), 2309-2315.
[http://dx.doi.org/10.2337/diabetes.48.12.2309] [PMID: 10580418]

Rabuazzo, A.M.; Buscema, M.; Vinci, C.; Caltabiano, V.; Vetri, M.; Forte, F.; Vigneri, R.; Purrello, F. Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms. Endocrinology, 1992, 131(4), 1815-1820.
[http://dx.doi.org/10.1210/endo.131.4.1396327] [PMID: 1396327]

Schrijnders, D.; Wever, R.; Kleefstra, N.; Houweling, S.T.; van Hateren, K.J.; de Bock, G.H.; Bilo, H.J.; Groenier, K.H.; Landman, G.W. Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39). Diabetes Obes. Metab., 2016, 18(10), 973-979.
[http://dx.doi.org/10.1111/dom.12700] [PMID: 27265756]

Phung, O.J.; Scholle, J.M.; Talwar, M.; Coleman, C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA, 2010, 303(14), 1410-1418.
[http://dx.doi.org/10.1001/jama.2010.405] [PMID: 20388897]

Marre, M.; Howlett, H.; Lehert, P.; Allavoine, T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet. Med., 2002, 19(8), 673-680.
[http://dx.doi.org/10.1046/j.1464-5491.2002.00774.x] [PMID: 12147149]

Ristic, S.; Collober-Maugeais, C.; Pecher, E.; Cressier, F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet. Med., 2006, 23(7), 757-762.
[http://dx.doi.org/10.1111/j.1464-5491.2006.01914.x] [PMID: 16842480]

Charbonnel, B.; Schernthaner, G.; Brunetti, P.; Matthews, D.R.; Urquhart, R.; Tan, M.H.; Hanefeld, M. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia, 2005, 48(6), 1093-1104.
[http://dx.doi.org/10.1007/s00125-005-1751-1] [PMID: 15889234]

Göke, B.; Gallwitz, B.; Eriksson, J.; Hellqvist, A.; Gause-Nilsson, I. D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int. J. Clin. Pract., 2010, 64(12), 1619-1631.
[http://dx.doi.org/10.1111/j.1742-1241.2010.02510.x] [PMID: 20846286]

Ferrannini, E.; Fonseca, V.; Zinman, B. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab., 2009.

Alejandro Akrouh1, S. Eliza Halcomb2, Colin G. Nichols1 and monica sala-rabanal1,molecular biology of KATP channels and implications for health and Disease. IUBMB Life, 2009, 61(10), 971-978.
[http://dx.doi.org/10.1002/iub.246] [PMID: 19787700]

Lebovitz, H.E.; Melander, A. Sulfonylureas: Basic Aspects and Clinical Uses[M]// International Textbook of Diabetes Mellitus; John Wiley Sons Ltd: Hoboken. , 2004.

Furman, B.L. Meglitinide, Reference Module in Biomedical Sciences; Elsevier: Amsterdam, 2017.

Brasseur, R.; Ruysschaert, J.M. Conformation and mode of organization of amphiphilic membrane components: A conformational analysis. Biochem. J., 1986, 238, 1-11.
[http://dx.doi.org/10.1042/bj2380001]

Lins, L.; Brasseur, R. The hydrophobic effect in protein folding. FASEB J., 1995, 9(7), 535-540.
[http://dx.doi.org/10.1096/fasebj.9.7.7737462] [PMID: 7737462]

Malaisse, WJ Insulinotropic effect of (2S)-2-benzyl-3(cis-hexahydro-2-isoindolinylcarbonyl) propionate. II. Ionophoretic and conformational aspects. Gen. Phamuaco., 1995, 126, 1319-1325.

Malaisse, W.J. Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur. J. Clin. Invest., 1999, 29(S2)(Suppl. 2), 21-29.
[http://dx.doi.org/10.1046/j.1365-2362.1999.00001.x] [PMID: 10383607]

Willy, J. Pharmacology of the meglitinide analogs new treatment options for type 2 diabetes mellitus, treatments in endocrinology. Treat. Endocrinol., 2003, 2(6), 401-414.

Malaisse, W.J.; Brasseur, R. Bakkali Nadi, A Conformation analysis of non-sulfonylurea hypoglycemic agents in the meglitinide family [J]. Biochem. Pharmacol., 1995, 50(2), 1879-1884.

McLeod, J.F. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin. Pharmacokinet., 2004, 43(2), 97-120.
[http://dx.doi.org/10.2165/00003088-200443020-00003] [PMID: 14748619]

Hollingdal, M.; Sturis, J.; Gall, M.A.; Damsbo, P.; Pincus, S.; Veldhuis, J.D.; Pørksen, N.; Schmitz, O.; Juhl, C.B. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabet. Med., 2005, 22(10), 1408-1413.
[http://dx.doi.org/10.1111/j.1464-5491.2005.01652.x] [PMID: 16176204]

Blicklé, J.F. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab., 2006, 32(2), 113-120.
[http://dx.doi.org/10.1016/S1262-3636(07)70257-4] [PMID: 16735959]

Del Prato, S.; Heine, R.J.; Keilson, L.; Guitard, C.; Shen, S.G.; Emmons, R.P. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care, 2003, 26(7), 2075-2080.
[http://dx.doi.org/10.2337/diacare.26.7.2075] [PMID: 12832316]

Culy, C.R.; Jarvis, B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs, 2001, 61(11), 1625-1660.
[http://dx.doi.org/10.2165/00003495-200161110-00008] [PMID: 11577798]

Sakura, H.; Wat, N.; Horton, V.; Millns, H.; Turner, R.C.; Ashcroft, F.M. Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia, 1996, 39(10), 1233-1236.
[http://dx.doi.org/10.1007/BF02658512] [PMID: 8897013]

Nagashima, K.; Takahashi, A.; Ikeda, H.; Hamasaki, A.; Kuwamura, N.; Yamada, Y.; Seino, Y. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity. Diabetes Res. Clin. Pract., 2004, 66(Suppl. 1), S75-S78.
[http://dx.doi.org/10.1016/j.diabres.2003.12.011] [PMID: 15563985]

Ashcroft, S.J.H. The β-cell K(ATP) channel. J. Membr. Biol., 2000, 176(3), 187-206.
[PMID: 10931971]

Sunaga, Y.; Gonoi, T.; Shibasaki, T.; Ichikawa, K.; Kusama, H.; Yano, H.; Seino, S. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur. J. Pharmacol., 2001, 431(1), 119-125.
[http://dx.doi.org/10.1016/S0014-2999(01)01412-1] [PMID: 11716850 ]

Manning Fox, J.E.; Kanji, H.D.; French, R.J.; Light, P.E. Cardioselectivity of the sulphonylurea HMR 1098: studies on native and recombinant cardiac and pancreatic K(ATP) channels. Br. J. Pharmacol., 2002, 135(2), 480-488.
[http://dx.doi.org/10.1038/sj.bjp.0704455] [PMID: 11815384]

Reimann, F.; Proks, P.; Ashcroft, F.M. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br. J. Pharmacol., 2001, 132(7), 1542-1548.
[http://dx.doi.org/10.1038/sj.bjp.0703962] [PMID: 11264248]

Butler, P. Pulsatile Insulin Secretion[M]//Mechanisms and Biological Significance of Pulsatile Hormone Secretion. Novartis Foundation Symposium, Portland 2272008.

Pørksen, N.; Hollingdal, M.; Juhl, C.; Butler, P.; Veldhuis, J.D.; Schmitz, O. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes, 2002, 51(Suppl. 1), S245-S254.
[http://dx.doi.org/10.2337/diabetes.51.2007.S245] [PMID: 11815487]

Weir, G.C.; Bonner-Weir, S. Five stages of evolving β-cell dysfunction during progression to diabetes. Diabetes, 2004, 53(Suppl. 3), S16-S21.
[http://dx.doi.org/10.2337/diabetes.53.suppl_3.S16] [PMID: 15561905]

Del Prato, S.; Tiengo, A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab. Res. Rev., 2001, 17(3), 164-174.
[http://dx.doi.org/10.1002/dmrr.198] [PMID: 11424229]

Bruce, D.G.; Storlien, L.H.; Furler, S.M.; Chisholm, D.J. Cephalic phase metabolic responses in normal weight adults. Metabolism, 1987, 36(8), 721-725.
[http://dx.doi.org/10.1016/0026-0495(87)90106-5] [PMID: 3298939]

Mitrakou, A.; Kelley, D.; Mokan, M.; Veneman, T.; Pangburn, T.; Reilly, J.; Gerich, J. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med., 1992, 326(1), 22-29.
[http://dx.doi.org/10.1056/NEJM199201023260104] [PMID: 1727062]

Calles-Escandon, J.; Robbins, D.C. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes, 1987, 36(10), 1167-1172.
[http://dx.doi.org/10.2337/diab.36.10.1167] [PMID: 2888695]

Basu, A.; Alzaid, A.; Dinneen, S.; Caumo, A.; Cobelli, C.; Rizza, R.A. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J. Clin. Invest., 1996, 97(10), 2351-2361.
[http://dx.doi.org/10.1172/JCI118678] [PMID: 8636416]

Fuhlendorff, J.; Rorsman, P.; Kofod, H.; Brand, C.L.; Rolin, B.; MacKay, P.; Shymko, R.; Carr, R.D. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes, 1998, 47(3), 345-351.
[http://dx.doi.org/10.2337/diabetes.47.3.345] [PMID: 9519738]

Li, L.; Yang, M.; Li, Z.; Yan, X.; Guo, H.; Pan, H.; Liu, H.; Liao, Y.; Yang, G. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial. Diabetes Obes. Metab., 2012, 14(2), 187-189.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01494.x] [PMID: 21895920]

Leslie, S. Satin, Peter C. Butler, Joon Ha, Arthur S. Sherman, Pulsatile insulinsecretion, impaired glucose tolerance and type 2 diabetes. Mol. Aspects Med., 2015, 42, 61-77.
[http://dx.doi.org/10.1016/j.mam.2015.01.003]

Juhl, C.B.; Pørksen, N.; Hollingdal, M.; Sturis, J.; Pincus, S.; Veldhuis, J.D.; Dejgaard, A.; Schmitz, O. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Diabetes Care, 2000, 23(5), 675-681.
[http://dx.doi.org/10.2337/diacare.23.5.675] [PMID: 10834429]

Song, S.H.; McIntyre, S.S.; Shah, H.; Veldhuis, J.D.; Hayes, P.C.; Butler, P.C. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J. Clin. Endocrinol. Metab., 2000, 85(12), 4491-4499.
[http://dx.doi.org/10.1210/jc.85.12.4491] [PMID: 11134098]

Ritzel, R.A.; Veldhuis, J.D.; Butler, P.C. The mass, but not the frequency, of insulin secretory bursts in isolated human islets is entrained by oscillatory glucose exposure. Am. J. Physiol. Endocrinol. Metab., 2006, 290(4), E750-E756.
[http://dx.doi.org/10.1152/ajpendo.00381.2005] [PMID: 16278244]

Yesildag, B.; Bock, T.; Herrmanns, K. Kin of IRRE-Like Protein 2 is a phosphorylated glycoprotein that regulates basal insulin secretion. J. Biol. Chem., 2015, 290(43), 25891-25906.

Aldhahi, W.; Armstrong, J.; Bouche, C.; Carr, R.D.; Moses, A.; Goldfine, A.B. Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia. J. Clin. Endocrinol. Metab., 2004, 89(9), 4553-4557.
[http://dx.doi.org/10.1210/jc.2004-0266] [PMID: 15356061]

Palerm, C.C.; Bequette, B.W. Hypoglycemia detection and prediction using continuous glucose monitoring-a study on hypoglycemic clamp data. J. Diabetes Sci. Technol., 2007, 1(5), 624-629.
[http://dx.doi.org/10.1177/193229680700100505] [PMID: 19885130]

Malmgren, S.; Ahrén, B. Deciphering the hypoglycemic glucagon response: development of a graded hyperinsulinemic hypoglycemic clamp technique in female mice. Endocrinology, 2015, 156(10), 3866-3871.
[http://dx.doi.org/10.1210/EN.2015-1314] [PMID: 26132921]

Moses, R. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin. Pharmacother., 2000, 1(7), 1455-1467.
[http://dx.doi.org/10.1517/14656566.1.7.1455] [PMID: 11249478]

Esposito, K.; Giugliano, D.; Nappo, F.; Marfella, R. Campanian Postprandial Hyperglycemia Study Group.Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation, 2004, 110(2), 214-219.
[http://dx.doi.org/10.1161/01.CIR.0000134501.57864.66] [PMID: 15197140]

Saisho, Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int. J. Mol. Sci., 2014, 15(10), 18381-18406.
[http://dx.doi.org/10.3390/ijms151018381] [PMID: 25314300]

Rizzo, M.R.; Marfella, R.; Barbieri, M.; Boccardi, V.; Vestini, F.; Lettieri, B.; Canonico, S.; Paolisso, G. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care, 2010, 33(10), 2169-2174.
[http://dx.doi.org/10.2337/dc10-0389] [PMID: 20573753]

Ohara, T.; Doi, Y.; Ninomiya, T.; Hirakawa, Y.; Hata, J.; Iwaki, T.; Kanba, S.; Kiyohara, Y. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology, 2011, 77(12), 1126-1134.
[http://dx.doi.org/10.1212/WNL.0b013e31822f0435] [PMID: 21931106]

Abbink, E.J.; van der Wal, P.S.; Sweep, C.G.; Smits, P.; Tack, C.J. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation. Diabetes Metab. Res. Rev., 2004, 20(6), 466-471.
[http://dx.doi.org/10.1002/dmrr.474] [PMID: 15386823]

Barnett, A.H.; Anderson, D.M.; Shelley, S.; Morgan, R.; Owens, D.R. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes. Diabetes Obes. Metab., 2004, 6(2), 104-113.
[http://dx.doi.org/10.1111/j.1462-8902.2004.00321.x] [PMID: 14746575]

Damsbo, P.; Clauson, P.; Marbury, T.C.; Windfeld, K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care, 1999, 22(5), 789-794.
[http://dx.doi.org/10.2337/diacare.22.5.789] [PMID: 10332683]

Gerich, J.; Raskin, P.; Jean-Louis, L.; Purkayastha, D.; Baron, M.A. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care, 2005, 28(9), 2093-2099.
[http://dx.doi.org/10.2337/diacare.28.9.2093] [PMID: 16123472]

Omori, Kazuno; Nomoto, Hiroshi Nakamura, Akinobu Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. J. Diab. Invest., 2018, 10(2), 1-8.

Yajima, T.; Yajima, K.; Hayashi, M.; Takahashi, H.; Yasuda, K. Serum albumin-adjusted glycated albumin as a better indicator of glycemic control in Type 2 diabetes mellitus patients with short duration of hemodialysis. Diabetes Res. Clin. Pract., 2017, 130, 148-153.
[http://dx.doi.org/10.1016/j.diabres.2017.05.020] [PMID: 28641154]

Yin, J.; Jin, D.; Wang, H. Serum glycated albumin is superior to hemoglobin A1c for correlating with HMGB1 in coronary artery disease with type 2 diabetic mellitus patients. Int. J. Clin. Exp. Med., 2015, 8(4), 4821-4825.
[PMID: 26131056]

Pan, J.; Li, Q.; Zhang, L.; Jia, L.; Tang, J.; Bao, Y.; Jia, W. Serum glycated albumin predicts the progression of diabetic retinopathy--a five year retrospective longitudinal study. J. Diabetes Complications, 2014, 28(6), 772-778.
[http://dx.doi.org/10.1016/j.jdiacomp.2014.06.015] [PMID: 25073934]

Kondaveeti, S.B. D, K.; Mishra, S.; Kumar R, A.; Shaker, I.A. Evaluation of glycated albumin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus. J. Clin. Diagn. Res., 2013, 7(7), 1280-1283.
[PMID: 23998045]

Koga, M.; Murai, J.; Saito, H.; Kasayama, S. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care, 2010, 33(2), 270-272.
[http://dx.doi.org/10.2337/dc09-1002] [PMID: 19846794]

Ogawa, A.; Hayashi, A.; Kishihara, E.; Yoshino, S.; Takeuchi, A.; Shichiri, M. New indices for predicting glycaemic variability. PLoS One, 2012, 7(9)e46517
[http://dx.doi.org/10.1371/journal.pone.0046517] [PMID: 23029543]

Hay, L.C.; Wilmshurst, E.G.; Fulcher, G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol. Ther., 2003, 5(1), 19-26.
[http://dx.doi.org/10.1089/152091503763816427] [PMID: 12725703]

Gehlaut, R.R.; Dogbey, G.Y.; Schwartz, F.L.; Marling, C.R.; Shubrook, J.H. Hypoglycemia in type 2 diabetes–more common than you think: a continuous glucose monitoring study. J. Diabetes Sci. Technol., 2015, 9(5), 999-1005.
[http://dx.doi.org/10.1177/1932296815581052] [PMID: 25917335]

Nomoto, H.; Sekizaki, T.; Jyoudo, S. The effect of switching from sulfonlylureas to repaglinide -observational trial. Diabetes Front, 2015, 26, 613-617.

Lang, V.; Youssef, N.; Light, P.E. The molecular genetics of sulfonylurea receptors in the pathogenesis and treatment of insulin secretory disorders and type 2 diabetes. Curr. Diab. Rep., 2011, 11(6), 543-551.
[http://dx.doi.org/10.1007/s11892-011-0233-8] [PMID: 21968738]

Olson, T.M.; Terzic, A.; Human, K. ATP) channelopathies: diseases of metabolic homeostasis. Pflugers Arch., 2010, 460(2), 295-306.
[http://dx.doi.org/10.1007/s00424-009-0771-y] [PMID: 20033705]

Scarsi, M.; Podvinec, M.; Roth, A.; Hug, H.; Kersten, S.; Albrecht, H.; Schwede, T.; Meyer, U.A.; Rücker, C. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol. Pharmacol., 2007, 71(2), 398-406.
[http://dx.doi.org/10.1124/mol.106.024596] [PMID: 17082235]

Perfetti, R.; D’Amico, E. Rational drug design and PPAR agonists. Curr. Diab. Rep., 2005, 5(5), 340-345.
[http://dx.doi.org/10.1007/s11892-005-0091-3] [PMID: 16188168]

Staels, B.; Fruchart, J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes, 2005, 54(8), 2460-2470.
[http://dx.doi.org/10.2337/diabetes.54.8.2460] [PMID: 16046315]

Martín, J.A.; Brooks, D.A.; Prieto, L.; González, R.; Torrado, A.; Rojo, I.; López de Uralde, B.; Lamas, C.; Ferritto, R.; Dolores Martín-Ortega, M.; Agejas, J.; Parra, F.; Rizzo, J.R.; Rhodes, G.A.; Robey, R.L.; Alt, C.A.; Wendel, S.R.; Zhang, T.Y.; Reifel-Miller, A.; Montrose-Rafizadeh, C.; Brozinick, J.T.; Hawkins, E.; Misener, E.A.; Briere, D.A.; Ardecky, R.; Fraser, J.D.; Warshawsky, A.M. 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. Bioorg. Med. Chem. Lett., 2005, 15(1), 51-55.
[http://dx.doi.org/10.1016/j.bmcl.2004.10.042] [PMID: 15582409]

Hazama, Y.; Matsuhisa, M.; Ohtoshi, K.; Gorogawa, S.; Kato, K.; Kawamori, D.; Yoshiuchi, K.; Nakamura, Y.; Shiraiwa, T.; Kaneto, H.; Yamasaki, Y.; Hori, M. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. Diabetes Res. Clin. Pract., 2006, 71(3), 251-255.
[http://dx.doi.org/10.1016/j.diabres.2005.08.004] [PMID: 16214255]